Bioray Pharmaceutical Co., Ltd.
Clinical trials sponsored by Bioray Pharmaceutical Co., Ltd., explained in plain language.
-
New drug BRY812 targets Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in 56 women with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The drug is given by injection to see if it can shrink tumors and how safe it is. The trial is in Phase IIa, meaning it is …
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:07 UTC
-
New gout pill aims to tame uric acid in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new tablet called BR2251 to see if it safely lowers uric acid levels in people with gout and high uric acid. About 160 adults aged 18 to 75 will receive either a low, medium, or high dose of BR2251 or a control drug for 12 weeks. The goal is to find the best do…
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 12:08 UTC